Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines

Cancer Letters

Volumn 279, Issue 1, 2009, Pages 57-64

  Duarte, Mariana Lemos ^a,b   Moraes, Emanuela de ^a   Pontes, Elizangela ^a   Schluckebier, Luciene ^a   Moraes, Joyce Luana de ^a   Hainaut, Pierre ^c   Ferreira, Carlos Gil ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Chemotherapy; Cyclooxygenase 2; Lung cancer; p53

Indexed keywords

CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; MESSENGER RNA; PACLITAXEL; PROSTAGLANDIN E2; PROTEIN P53;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INDUCTION; HUMANS; LUNG NEOPLASMS; MUTATION; PACLITAXEL; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349287439     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.021     Document Type: Article

References (28)

1. Niklinski J., and Hirsch F.R. Molecular approaches to lung cancer evaluation. Lung Cancer 38 3 (2002) S9-17
2. Castelao J.E., Bart R.D., DiPerna C.A., Sievers E.M., and Bremner R.M. Lung cancer and cyclooxygenase-2. Ann. Thorac. Surg. 76 (2003) 1327-1335
3. Riedl K., Krysan K., Põld M., Dalwadi H., Heuze-Vourc'h N., Dohadwala M., Liu M., Cui X., Figlin R., Mao J.T., Strieter R., Sharma S., and Dubinett S.M. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist. Updat. 7 (2004) 169-184
4. Dempke W., Rie C., Grothey A., and Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy?. J. Cancer Res. Clin. Oncol. 127 (2001) 411-417
5. Hosomi Y., Yokose T., Hirose Y., Nakajima R., Nagai K., Nishiwaki Y., and Ochiai A. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 30 (2000) 73-81
6. Ochiai M., Oguri T., Isobe T., Ishioka S., and Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn. J. Cancer Res. 90 (1999) 1338-1343
7. Brabender J., Park J., Metzger R., Schneider P.M., Lord R.V., Hölscher A.H., Danenberg K.D., and Danenberg P.V. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann. Surg. 235 (2002) 440-443
8. Krysan K., Dalwadi H., Sharma S., Põld M., and Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res. 64 (2004) 6359-6362
9. Huisman C., Ferreira C.G., Bröker L.E., Rodriguez J.A., Smit E.F., Postmus P.E., Kruyt F.A., and Giaccone G. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin. Cancer Res. 8 (2002) 596-606
10. Ojima I., Chakravarty S., Inoue T., Lin S., He L., Horwitz S.B., Kuduk S.D., and Danishefsky S.J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Nat. Acad. Sci. USA 96 (1999) 4256-4261
11. Ganansia-Leymarie V., Bischoff P., Bergerat J.P., and Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr. Med. Chem. Anticancer Agents 3 (2003) 291-306
12. Subbaramaiah K., Marmo T.P., Dixon D.A., and Dannenberg A.J. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J. Biol. Chem. 278 (2003) 37637-37647
13. Altorki N.K., Port J.L., Zhang F., Golijanin D., Thaler H.T., Duffield-Lillico A.J., Subbaramaiah K., and Dannenberg A.J. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin. Cancer Res. 11 (2005) 4191-4197
14. Wu K.K., Liou J.Y., and Cieslik K. Transcriptional Control of COX-2 via C/EBPbeta. Arterioscl. Thromb. Vasc. Biol. 25 (2005) 679-685
15. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 70 (2005) 658-667
16. Han J.A., Kim J.L., Ongusaha P.P., Hwang D.H., Ballou L.R., Mahale A., Aaronson S.A., and Lee S.W. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 21 (2002) 5635-5644
17. Benoit V., Moraes E., Dar N.A., Taranchon E., Bours V., Hautefeuille A., Taniere P., Chariot A., Scoazec J.Y., de Moura Gallo C.V., Merville M.P., and Hainaut P. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 25 (2006) 5708-5718
18. Moraes E., Dar N.A., de Moura Gallo C.V., and Hainaut P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int. J. Cancer 121 (2007) 929-937
19. Sengupta S., and Harris C.C. p53: Traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 6 (2005) 44-55
20. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., and Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274 (1999) 10911-10915
21. Breuer R.H.J., Postmus P.E., and Smit E.F. Molecular pathology of non-small-cell lung cancer. Respiration 72 (2005) 313-330
22. Brown J.R., and DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin. Cancer Res. 10 (2004) 4266s-4269s
23. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin. Cancer Res. 6 (2000) 4055-4063
24. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 47 (2003) 7265-7279
25. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 8 (2007) 573-584
26. Dittmann K.H., Mayer C., Ohneseit P.A., Raju U., Andratschke N.H., Milas L., and Rodemann H.P. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: A COX-2 independent mechanism. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 203-212
27. Krysan K., Merchant F.H., Zhu L., Dohadwala M., Luo J., Lin Y., Heuze-Vourc'h N., Pold M., Seligson D., Chia D., Goodglick L., Wang H., Strieter R., Sharma S., and Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 18 (2004) 206-208
28. Edelman M.J., Watson D., Wang X., et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B trial 30203. J. Clin. Oncol. 26 (2008) 848-855